Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NYU Langone Health
With
National Center for Complementary and Integrative Health (NCCIH)
This study aims to set the stage for a future definitive large-scale Phase III trial in patients with migraine and depressive symptoms. This first phase is aimed at fidelity optimization of MBCT-T and MBCT-V in people with migraine (defined by the International Classification of Headache Disorders - 3) and depressive symptoms (defined by empirical cut-offs on the Patient Health Questionnaire - 9).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently meets ICHD-3 criteria for migraine using the Structured Diagnostic Interview for Headache
Self-reported 4-14 headache days per month, with at least one attack meeting migraine criteria
Score between 5-14 on the PHQ-9
Age ≥ 18
Ability to read and speak English
Capacity to consent
You may not be if
Meeting ICHD-3 criteria for persistent headache attributed to traumatic injury to the head (post-traumatic headache) on the Structure Diagnostic Interview for Headache
Changes in preventive migraine medication or anti-depressant medication within 6 weeks of intake; changes in longer-term migraine prevention (onobotulinum toxin A, anti-calcitonin gene related peptide treatment) within 3 months of intake
Comorbid psychiatric illness or clinical features that would interfere with participant's ability to participate in or receive benefit from the MBCT intervention, including but not limited to: active suicidal ideation; recent history of psychosis or mania; borderline, histrionic or narcissistic personality disorder; cognitive impairment; sensory disabilities
Prior history of engaging in formal mindfulness-based interventions including: MBSR, MBCT, Acceptance and Commitment therapy, Dialectical Behavior Therapy
